A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The aim of this study is to evaluate the efficacy and safety of ESG401 as first-line treatment in patients with unresectable recurrent or metastatic triple-negative breast cancer.
Epistemonikos ID: 3fedee251d38661b8805a641273344a9c5677954
First added on: Jan 01, 2025